Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

皿治林 - NMPA Drug Approval Details

Approvals/NMPA/Mizolastine Sustained Release Tablets

Approved

化学药品

Mizolastine Sustained Release Tablets

THERABEL HEALTHCARE LIMITED🇨🇳 National Medical Products Administration

Approval Date: May 23, 2022
Approval ID: 6032a2a12d8e5c5d
Company: THERABEL HEALTHCARE LIMITED
Type: 化学药品

Approval Details

Approval Id: 6032a2a12d8e5c5d
Approval Number: 国药准字HJ20171171
Generic Name: 咪唑斯汀缓释片
Generic Name En: Mizolastine Sustained Release Tablets
Trade Name: 皿治林
Drug Type: 化学药品
Dosage Form: 片剂
Strength: 10mg
Reg Date: 2022-05-23
Expired Date: 2027-05-22
Company Name: THERABEL HEALTHCARE LIMITED
Production Company Name: SANOFI WINTHROP INDUSTRIE
Company Detail Path: /organization/therabel-healthcare-limited
Production Company Detail Path: /organization/sanofi-winthrop-industrie

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

May 23, 2022

Approval ID

6032a2a12d8e5c5d

Type

化学药品

Back to NMPA Approvals